Any content you receive is for information purposes only. Always conduct your own research.
*Disseminated on Behalf of Cardiol Therapeutics Inc.
Krypton Street Just Put (NASDAQ: CRDL) On The Radar For This Morning—Friday, October 2, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At (CRDL) While It’s Still Early… October 2, 2026 Dear Reader, We’re starting the morning with Cardiol Therapeutics Inc. (NASDAQ: CRDL) at the top of our radar as its pivotal cardiac program continues to advance. With Phase III enrollment already moving beyond its original target, there’s a lot here worth watching closely today. Heart inflammation is becoming one of the more interesting clinical development areas in cardiovascular medicine… The reason is simple: inflammation and fibrosis can sit at the center of conditions that repeatedly send patients back into care, yet the treatment path can still leave room for new approaches. That is where Cardiol Therapeutics Inc. (NASDAQ: CRDL) enters the picture. Which is just some of the reasons why (CRDL) is topping our watchlist this morning—Friday, October 2, 2026. 
The company is advancing CardiolRx™, an oral formulation designed to modulate inflammasome pathway activation, with its lead program now in a pivotal Phase III study for recurrent pericarditis. And the timing deserves a closer look… According to a market report, the global recurrent pericarditis market is estimated at $880M in 2026 and projected to reach $1.32B by 2030, representing a 10.8% CAGR. Cardiol’s own September corporate deck points to roughly 40,000 recurrent pericarditis patients in the United States and cites more than $1B in commercial potential for CardiolRx™ in this indication, based on a third-party market-access study completed in 2025. Those figures matter because Cardiol Therapeutics Inc. (CRDL) is no longer working only toward an early clinical signal. The company has moved into the pivotal stage, completed its original Phase III enrollment target ahead of guidance, and now expects a major clinical readout in mid-2027. That gives the story a much clearer sequence of milestones than it had even a few months ago. Recent analyst coverage The analyst page lists Edward Nash of Canaccord Genuity with a $10 target, Brandonb Folkes of H.C. Wainwright with a $9 target and Mayank Mamtani of B. Riley Securities with an $11 target. Those three targets suggest significant upside potential from (CRDL)’s recent $1.53 range. This is where the clinical story gets serious
The foundation starts with the Phase II MAvERIC study. In that study, 27 patients with recurrent pericarditis were enrolled, and 24 progressed into an extension period while continuing CardiolRx™ as background therapies were withdrawn. The September corporate deck reports a 3.7-point reduction from baseline in the numerical pain score at eight weeks, with a median of five days to resolution or near-resolution of pain. That is the kind of result that becomes more interesting when it is supported by several separate clinical measures rather than a single endpoint… The same deck reports that 71% of extension-period patients experienced no recurrence, while pericarditis events moved from 5.8 per year before the study to 0.9 per year during the study. It also reports 95% study-therapy compliance and describes CardiolRx™ as safe and well tolerated in the Phase II program. Then came another validation step. In July, the company announced that the Phase II findings had been published in the Journal of the American Heart Association, with the publication describing rapid and sustained reductions in pericarditis pain and inflammation, substantial reductions in yearly episodes, and a favorable safety and tolerability profile. That matters because a pivotal program is stronger when its design is grounded in a clinical dataset that has already been subjected to peer review… The company’s lead candidate is also differentiated by its intended profile. CardiolRx™ is an oral, pharmaceutically produced formulation, and the company says it is being developed as a non-immune-suppressing approach with disease-modifying potential. The company deck describes a high-concentration formulation with an industry-leading purity and stability profile, cGMP production, and a scalable manufacturing process. Mechanistically, the program is aimed at pathways tied to inflammation, oxidative stress, fibrosis, remodeling, mitochondrial function, and calcium handling. For (CRDL), that combination of clinical evidence, oral administration, and a defined biological mechanism is what turns the program from an interesting concept into a pivotal-stage cardiovascular story. The pivotal program just moved another step forward
The biggest recent development came on September 23… Cardiol Therapeutics Inc. (CRDL) announced that MAVERIC had reached its original 110-patient enrollment target ahead of the company’s end-of-September guidance. Rather than stopping there, the MAVERIC Steering Committee recommended expanding enrollment to as many as 150 patients after a blinded review showed fewer recurrences than had been anticipated. The company characterized that observation as encouraging. The Phase III update explains that the expansion is intended to capture enough events for a more robust assessment while preserving the planned statistical power of the study. That is an important distinction… The added enrollment is intended to support the event count needed for the study’s primary analysis after a blinded review found fewer recurrences than expected across patients randomized 1:1 to CardiolRx™ or placebo. MAVERIC is a multinational, double-blind, randomized, placebo-controlled pivotal study. Its primary efficacy analysis evaluates time to the first new episode of recurrent pericarditis, while a secondary endpoint looks at the proportion of patients free from a new recurrence at the end of the study. The corporate presentation says the program can enroll up to 150 patients across as many as 25 clinical sites, with topline results anticipated in mid-2027. That mid-2027 readout now becomes the central date on the calendar… There is another layer here that deserves attention. The U.S. FDA has granted CardiolRx™ Orphan designation for pericarditis, including recurrent pericarditis, according to the company’s September update. And after the recent enrollment expansion, the company said existing capital is expected to fund MAVERIC through completion, with a runway into Q1 2028. That financial timing was reinforced just one week earlier. On September 16, Cardiol announced it had received more than $7M from the exercise of outstanding common share purchase warrants. The funding update said the proceeds were expected to support operations through the pivotal MAVERIC readout and provide additional flexibility beyond that milestone. For (CRDL), that means the next major clinical event is paired with a stated capital runway extending beyond the expected readout. And the pipeline reaches beyond one indication
Recurrent pericarditis is the lead story, but it is not the entire story… CardiolRx™ has also been studied in acute myocarditis through the Phase II ARCHER program. The September presentation says ARCHER enrolled 109 adults across 34 sites in the United States, Brazil, France, and Israel. The study evaluated CardiolRx™ over 12 weeks and used cardiac magnetic resonance measures to examine changes in myocardial structure and function. That gives Cardiol Therapeutics Inc. (CRDL) a second completed Phase II cardiovascular program behind the same lead formulation. Then there is CRD-38… CRD-38 is a subcutaneously administered cannabidiol formulation being developed for inflammatory heart disease, including chronic heart failure and cardiomyopathy. The company describes the formulation as low viscosity, capable of carrying high concentrations of lipophilic active ingredient, and designed with a pharmacokinetic profile intended to support optimized dosing. Preclinical work summarized in the company deck shows cardioprotective effects in models of heart failure, including effects on hypertrophy, fibrosis, inflammation, and cardiac function. The same presentation identifies completion of the IND-enabling program and initiation of clinical development as future milestones for CRD-38. So while the mid-2027 MAVERIC readout is the clearest near-term focus, the broader pipeline gives the company additional ways to build value from its work on inflammation and fibrosis in heart disease… 7 Reasons Why We're Watching (CRDL) This Morning
—Friday, October 2, 2026…
1. Pivotal Enrollment. MAVERIC reached its original 110-patient target ahead of end-of-September guidance, and the Phase III update says enrollment is expanding to as many as 150 patients. 2. Mid-2027 Readout. The same clinical update sets mid-2027 as the expected timing for topline MAVERIC results after the expanded enrollment is completed. 3. Phase II Signal. The corporate deck reports a 3.7-point pain-score reduction at eight weeks, five-day median time to near-resolution of pain, and a drop in yearly pericarditis events from 5.8 to 0.9. 4. Peer-Reviewed Data. The Phase II recurrent pericarditis findings were published in JAHA, giving the pivotal program a peer-reviewed clinical foundation. 5. Runway Through Readout. More than $7M from warrant exercises strengthened the balance sheet, and the company update said those funds would support operations through the pivotal readout. 6. Second Formulation. CRD-38 is in IND-enabling development for inflammatory heart disease, with the company presentation identifying completion of that work and entry into clinical development as future milestones. 7. Analyst Targets. Recent entries on the analyst page show targets of $9, $10, and $11 from H.C. Wainwright, Canaccord Genuity, and B. Riley Securities. Take A Look At (CRDL) While It’s Still Early… 
The key with Cardiol Therapeutics Inc. (CRDL) is that several parts of the story are now converging at once… The lead program has moved into a pivotal trial, the original enrollment target was reached ahead of schedule, the study has been expanded to strengthen the eventual assessment, and the company has identified a mid-2027 readout as the next major clinical milestone. At the same time, Phase II data have been peer reviewed, the balance sheet has received more than $7M in fresh warrant proceeds, and CRD-38 gives the pipeline a second formulation aimed at a much broader cardiac setting. That combination makes (CRDL) a name worth following closely as the MAVERIC program advances toward its pivotal readout. The next several quarters should provide a clearer view of whether the Phase II signal can carry through a randomized Phase III setting… And that is the question that could define the next chapter for Cardiol. Take a close look at Cardiol Therapeutics Inc. (NASDAQ: CRDL) while it’s still early. Sincerely, Alex Ramsay
Managing Editor,
Krypton Street |
